

The HA Drug Advisory Committee (DAC), comprising doctors, clinical pharmacologists and pharmacists, systematically appraises new drugs every three months. DAC is supported by expert panels which provide specialist views on the selection of drugs for individual specialties.

**Drug Advisory Committee Oct 2018 Meeting Outcome**

	Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for rejection <sup>1</sup>
1	Alectinib	Alecensa	Malignant disease and immunosuppression	Pending	Pending further information
2	Ceritinib	Zykadia	Malignant disease and immunosuppression	Approved in principle	N/A
3	Crizotinib	Xalkori	Malignant disease and immunosuppression	Approved	N/A
4	Dabrafenib / Trametinib	Tafinlar / Mekinist	Malignant disease and immunosuppression	Pending	Pending further information
5	Daratumumab	Darzalex	Malignant disease and immunosuppression	Rejected	Lack of high quality level of evidence to demonstrate its efficacy
6	Dulaglutide	Trulicity	Endocrine system	Pending	Pending further information
7	Fulvestrant	Faslodex	Malignant disease and immunosuppression	Rejected	Alternative(s) available in HADF with comparable benefits
8	Ibrutinib	Imbruvica	Malignant disease and immunosuppression	Approved	N/A
9	Lenalidomide	Revlimid	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
10	Netupitant / Palonosetron	Akynzeo	Central nervous system	Approved	N/A
11	Nintedanib	Ofev	Respiratory system	Approved	N/A
12	Obinutuzumab	Gazyva	Malignant disease and immunosuppression	Approved in principle	N/A
13	Omalizumab	Xolair	Respiratory system	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
14	Pembrolizumab	Keytruda	Malignant disease and immunosuppression	Pending	Pending further information
15	Pemetrexed	Alimta	Malignant disease and immunosuppression	Approved	N/A
16	Ramucirumab	Cyramza	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
17	Trifluridine/tipiracil	Lonsurf	Malignant disease and immunosuppression	Rejected	Insufficient evidence to demonstrate significant clinical outcome benefits
18	Ustekinumab	Stelara	Gastro-intestinal system	Pending	Pending further information

<sup>1</sup> The evaluation embraces the principles of safety, efficacy and cost-effectiveness and takes into account other relevant factors, including international recommendations and practices, advance in technology, disease state, patient compliance, quality of life, actual experience in the use of drugs as well as views of professionals and patients groups.